- $771.42m
- $1.01bn
- $38.47m
Annual income statement for Apnimed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 8.01 | 38.5 |
| Cost of Revenue | ||
| Gross Profit | 4.64 | 31.8 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 122 | 92.3 |
| Operating Profit | -114 | -53.8 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -109 | -58.1 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -109 | -58.1 |
| Net Income Before Extraordinary Items | ||
| Extraordinary Items | ||
| Net Income | -111 | -128 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -111 | -128 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -2.73 | -1.46 |